Cargando…

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St. Louis to evaluate whether it benefited our patient population. Patients were risk-assessed using the Memorial Sloan Kettering Predictive Nom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schenone, Aaron D, Luo, Jingqin, Montgomery, Luke, Morgensztern, Daniel, Adkins, Douglas R, Van Tine, Brian A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101751/ https://www.ncbi.nlm.nih.gov/pubmed/24574357 http://dx.doi.org/10.1002/cam4.209

Ejemplares similares

Adjuvant Chemotherapy of Soft Tissue Sarcoma—Current Status
por: Judson, Ian
Publicado: (2000)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: A Clinical Practice Guideline
por: Figueredo, Alvaro, et al.
Publicado: (2002)

Adjuvant chemotherapy in soft tissue sarcomas…Conflicts, consensus, and controversies
por: Bajpai, Jyoti, et al.
Publicado: (2016)

Adjuvant chemotherapy—Radiotherapy—Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases
por: Schliemann, Christoph, et al.
Publicado: (2018)

Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: Which Patients Benefit from Adjuvant Radiation Therapy and How Much?
por: Million, Lynn, et al.
Publicado: (2012)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Surgical resection with adjuvant brachytherapy in soft tissue sarcoma of the extremity – a case report
por: Guzik, Grzegorz, et al.
Publicado: (2012)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma
por: Schmitt, Thomas, et al.
Publicado: (2011)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience
por: Brunello, Antonella, et al.
Publicado: (2015)

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
por: Pacilio, C, et al.
Publicado: (2006)

ASO Author Reflections: Benefit of Adjuvant Radiotherapy for Clinical Outcome in Patients with Soft Tissue Sarcoma
por: Haas, R. L., et al.
Publicado: (2018)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.
por: Ravaud, A., et al.
Publicado: (1992)

Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas
por: Cortesi, Annalisa, et al.
Publicado: (2017)

Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
por: Brodowicz, Thomas, et al.
Publicado: (2000)

Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials.
por: Tierney, J. F., et al.
Publicado: (1995)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Results of resection of forearm soft tissue sarcoma
por: Nakata, Eiji, et al.
Publicado: (2023)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Flap Reconstruction Outcome Following Surgical Resection of Soft Tissue and Bone Sarcoma in the Setting of (Neo)adjuvant Therapy: A Sarcoma Center Experience
por: Lese, Ioana, et al.
Publicado: (2023)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Case Report: An Adolescent Soft Tissue Sarcoma With YWHAE-NUTM2B Fusion Is Effectively Treated With Combined Therapy of Epirubicin and Anlotinib
por: He, Jiajia, et al.
Publicado: (2022)

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma
por: Van Tine, Brian A, et al.
Publicado: (2021)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
por: Zhang, Jin, et al.
Publicado: (2021)

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
por: Hirbe, Angela C., et al.
Publicado: (2018)

Complex Vascular Resections for Retroperitoneal Soft Tissue Sarcoma
por: Devaud, Nicolas A., et al.
Publicado: (2023)

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.
por: Llombart-Cussac, A., et al.
Publicado: (1998)

A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy
por: Liu, Ching-Wen, et al.
Publicado: (2016)

Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study
por: Kawamura, Hidetaka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2cif52kkel345c48ec9v2s3u96